Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous SIRPa-depleted activated macrophages SI-101

A preparation of autologous macrophages that are ex vivo activated and depleted of signal-regulatory protein alpha (SIRP-alpha; SIRPa; CD172a), with potential immunostimulatory and antineoplastic activities. Upon reintroduction into the patient, autologous SIRPa-depleted activated macrophages SI-101 elicits an anti-tumor immune response via the phagocytosis of tumor cells. In addition, the autologous SIRPa-depleted activated macrophages SI-101 promotes a pro-inflammatory tumor microenvironment (TME) and activates a cancer neoantigen-specific cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. The depletion of SIRPa, an inhibitory protein expressed on macrophages and dendritic cells (DCs), prevents SIRPa/CD47-mediated inhibition of macrophage activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous SIRPa-low macrophages SI-101
US brand name:SIRPant-M
Code name:SI 101
SI-101
SI101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search